[go: up one dir, main page]

WO2010073011A3 - Heterocyclic compounds and their use as ampk activators - Google Patents

Heterocyclic compounds and their use as ampk activators Download PDF

Info

Publication number
WO2010073011A3
WO2010073011A3 PCT/GB2009/002945 GB2009002945W WO2010073011A3 WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3 GB 2009002945 W GB2009002945 W GB 2009002945W WO 2010073011 A3 WO2010073011 A3 WO 2010073011A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compounds
ampk activators
ampk
compounds
cardioprotection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/002945
Other languages
French (fr)
Other versions
WO2010073011A2 (en
Inventor
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of WO2010073011A2 publication Critical patent/WO2010073011A2/en
Publication of WO2010073011A3 publication Critical patent/WO2010073011A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

There is provided a compound of formula (I), wherein the dotted lines, X, T, G, Y, A1 to A5 and D1 to D5 have meanings given in the description, which compounds are useful in the treatment of conditions or disorders ameliorated by the activation of AMPK, for example skin diseases, lung disease, obesity, dry-type age-related macular degeneration, cardioprotection or, preferably, hyperinsulinemia, diabetes, cancer, fibrosis, neurodegenerative diseases, sexual dysfunction, heart failure, inflammation and osteoporosis.
PCT/GB2009/002945 2008-12-23 2009-12-22 Compounds useful as medicaments Ceased WO2010073011A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US19377408P 2008-12-23 2008-12-23
US61/193,774 2008-12-23
US20208409P 2009-01-27 2009-01-27
US61/202,084 2009-01-27
US20287909P 2009-04-15 2009-04-15
US61/202,879 2009-04-15
US24146309P 2009-09-11 2009-09-11
US61/241,463 2009-09-11

Publications (2)

Publication Number Publication Date
WO2010073011A2 WO2010073011A2 (en) 2010-07-01
WO2010073011A3 true WO2010073011A3 (en) 2010-09-23

Family

ID=42061073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002945 Ceased WO2010073011A2 (en) 2008-12-23 2009-12-22 Compounds useful as medicaments

Country Status (1)

Country Link
WO (1) WO2010073011A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN108578682B (en) * 2018-07-13 2022-04-12 浙江省医学科学院 Application of exenatide in the preparation of medicine for treating pulmonary fibrosis

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003467A2 (en) 2011-06-27 2013-01-03 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
ES2882807T3 (en) 2011-09-16 2021-12-02 Novartis Ag N-substituted heterocyclyl carboxamides
CN103467417B (en) * 2012-06-07 2015-05-20 中国科学院上海药物研究所 Arctigenin carboxamide derivative, preparation method thereof, composition comprising arctigenin carboxamide derivative and uses thereof
US8877980B2 (en) * 2012-09-11 2014-11-04 Al-Urdonia Lemudaddat Al-Ajsam Co. Phenylboronic acid
BR112015021985B1 (en) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS THEREOF, THEIR USES AND COMPOSITION
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
HRP20181670T1 (en) 2014-06-03 2018-12-14 Idorsia Pharmaceuticals Ltd PIRAZOL COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CALCIUM BLOCKERS
ES2693052T3 (en) 2014-09-15 2018-12-07 Idorsia Pharmaceuticals Ltd Triazole compounds as blockers of the T-type calcium channels
DK3394040T3 (en) 2015-12-24 2022-03-28 Univ California CFTR REGULATORS AND PROCEDURES FOR USING IT
JP6894902B2 (en) * 2015-12-24 2021-06-30 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア CFTR regulator and how to use it
JP6755778B2 (en) * 2016-11-11 2020-09-16 花王株式会社 PPARα activator
US11213517B2 (en) 2016-12-16 2022-01-04 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a T-type calcium channel blocker
ES2971626T3 (en) 2017-02-06 2024-06-06 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
CA3073718A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions
WO2019070709A1 (en) * 2017-10-02 2019-04-11 The Regents Of The University Of California Compounds for treating or preventing flavivirus infections
CN114728919B (en) * 2019-11-05 2025-12-30 德米拉公司 MrgprX2 antagonists and their uses
CN119661470A (en) * 2024-12-02 2025-03-21 安徽医科大学 A thiadiazole urone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2005085220A1 (en) * 2004-02-26 2005-09-15 Merck Patent Gmbh Use of thiadiazole urea derivatives
WO2007002461A1 (en) * 2005-06-23 2007-01-04 Dr. Reddy's Laboratories Ltd. 3,4-substituted thiazoles as ampk activators
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2511371A (en) 1945-03-12 1950-06-13 Monsanto Chemicals Sulfa derivatives of 2-amino-5-alkenyl-1, 3, 4-thiadiazoles
US2420434A (en) 1945-03-12 1947-05-13 Monsanto Chemicals 2-amino-5-alkenyl-1, 3, 4 thiadiazoles and process for making the same
US2524729A (en) 1945-03-12 1950-10-03 Monsanto Chemicals 2-amino-5-benzyl-1, 3, 4-thiadiazole and acid salts thereof
US3720685A (en) 1970-07-15 1973-03-13 Squibb & Sons Inc 3-amino-5-benzyl-1,2,4-oxadiazoles
US4054665A (en) 1974-11-29 1977-10-18 Sandoz, Inc. 2-Amino-5-(trifluoromethylphenylalkyl)-1,3,4 thiadiazoles used in the treatment of insomnia and anxiety
CH602685A5 (en) 1975-12-01 1978-07-31 Merck Patent Gmbh
DE2611965A1 (en) 1976-03-20 1977-09-29 Merck Patent Gmbh (1,3,4)-Thiadiazole-(5)-thiols prodn. - by solvolysis of corresp. S-(thio)acyl derivs. or their thione tautomers, useful as intermediates for pharmaceuticals
JP3258771B2 (en) 1992-11-16 2002-02-18 株式会社豊田製作所 Jig for measuring runout of brake rotor
JP2005538975A (en) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド 3- (Hetero) arylmethoxypyridines and their analogs as p38 MAP kinase inhibitors
US7262020B2 (en) 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
CA2610196A1 (en) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP1906955A2 (en) 2005-07-21 2008-04-09 Betagenon AB Use of thiazole derivatives and analogues in the treatment of cancer
CA2628863A1 (en) 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
WO2008029266A1 (en) 2006-09-08 2008-03-13 Glenmark Pharmaceuticals S.A. Stearoyl coa desaturase inhibitors
AU2007323193A1 (en) 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
US20100120669A1 (en) 2007-02-28 2010-05-13 Anne Marie Jeanne Bouillot Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2005085220A1 (en) * 2004-02-26 2005-09-15 Merck Patent Gmbh Use of thiadiazole urea derivatives
WO2007002461A1 (en) * 2005-06-23 2007-01-04 Dr. Reddy's Laboratories Ltd. 3,4-substituted thiazoles as ampk activators
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2009, GOLDFARB, DAVID SCOTT: "Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds", XP002593929, retrieved from STN Database accession no. 2009:846107 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN108578682B (en) * 2018-07-13 2022-04-12 浙江省医学科学院 Application of exenatide in the preparation of medicine for treating pulmonary fibrosis

Also Published As

Publication number Publication date
WO2010073011A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010073011A3 (en) Heterocyclic compounds and their use as ampk activators
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
PL2150530T3 (en) Substituted sulfonamide derivatives
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2008091540A3 (en) 23-substituted bile acids as tgr5 modulators and methods of use thereof
TNSN07431A1 (en) Imidazoquinolines as lipid kinase inhibitors
WO2010141796A3 (en) PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
MX2011010347A (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof.
WO2006037982A3 (en) Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases
WO2010080756A3 (en) Harmine derivatives for reducing body weight
WO2009120660A3 (en) Substituted pyridoxazines
EP2826472A3 (en) Telomerase activating compounds and their use
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2011025982A3 (en) Tetracycline compounds
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801242

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09801242

Country of ref document: EP

Kind code of ref document: A2